硝酸芬替康唑(Fenticonazole Nitrate) - 药物靶点：Ergosterol_在研适应症：真菌病，外阴阴道念珠菌病，足癣_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Fenticonazole、Fenticonazole nitrate (USAN)

+ [3]

靶点

Ergosterol

作用机制

麦角固醇生物合成抑制剂

治疗领域

感染泌尿生殖系统疾病皮肤和肌肉骨骼疾病

在研适应症

真菌病外阴阴道念珠菌病足癣+ [1]

非在研适应症-

原研机构-

在研机构

南京海纳医药科技股份有限公司

开封制药（集团）有限公司

北京美迪康信医药科技有限公司

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构

分子式C24H20Cl2N2OS

InChIKeyZCJYUTQZBAIHBS-UHFFFAOYSA-N

CAS号72479-26-6

查看全部结构式(2)

关联

8

项与硝酸芬替康唑相关的临床试验

CTR20130444 / Completed

硝酸芬替康唑阴道软胶囊治疗外阴阴道假丝酵母菌病多中心、随机盲法、剂量探索临床试验

探索硝酸芬替康唑阴道软胶囊治疗外阴阴道假丝酵母菌病的剂量

开始日期-

申办/合作机构-

CTR20170167 / Recruiting临床3期

硝酸芬替康唑栓治疗外阴阴道假丝酵母菌病多中心、随机、剂量、疗程探索临床研究

评价硝酸芬替康唑栓治疗外阴阴道假丝酵母菌病的有效性和安全性

开始日期2016-08-09

申办/合作机构

山东特瑞林医药科技发展有限公司

CTR20130309 / Active, not recruiting临床2期

评价硝酸芬替康唑栓的有效性和安全性的多中心、随机、盲法、阳性药物平行对照II期临床试验

评价硝酸芬替康唑栓治疗外阴阴道念珠菌病的有效性和安全性，探索硝酸芬替康唑栓治疗外阴阴道念珠菌病的临床使用剂量。

开始日期2014-08-05

申办/合作机构

北京美迪康信医药科技有限公司

100 项与硝酸芬替康唑相关的临床结果

登录后查看更多信息

100 项与硝酸芬替康唑相关的转化医学

登录后查看更多信息

100 项与硝酸芬替康唑相关的专利（医药）

登录后查看更多信息

88

项与硝酸芬替康唑相关的文献（医药）

2024-12-01·Antonie van Leeuwenhoek

Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species

Article

作者: Kharazi, Mahboobeh ; Motamedi, Marjan ; Jabrodini, Ahmad ; Rezaei Arab, Maryam ; Shariat, Sahar ; Zomorodian, Kamiar ; Shabanzadeh, Shafigheh ; Ghasemi, Farnia ; Yazdanpanah, Somayeh

Candida onychomycosis is a common fungal infection affecting the nails, primarily caused by Candida (C.) species. Regarding the increasing trend of Candida onychomycosis and the antifungal resistant phenomenon in recent years, this study aims to evaluate the epidemiological characteristics of Candida onychomycosis, the distribution of emerging species, and the antifungal susceptibility profiles of isolates. Onychomycosis caused by yeast species was confirmed through direct examination and culture of nail scraping among all individuals suspected to have onychomycosis and referred to a medical mycology laboratory between June 2019 and March 2022. Species of yeast isolates were identified using the multiplex PCR and PCR-RFLP methods. The antifungal susceptibility of isolates to common antifungal agents and imidazole drugs was evaluated according to the M-27-A3 CLSI protocol. Among 101 yeast strains isolated from onychomycosis, Candida parapsilosis complex (50.49%) was the most common species, followed by C. albicans (20.79%) and C. tropicalis (10.89%). Rare species of yeasts such as C. guilliermondii and Saccharomyces cerevisiae were also identified by molecular methods. Results obtained from antifungal susceptibility testing showed significant differences in MIC values of isoconazole, fenticonazole, and sertaconazole among different species. Overall, a fluconazole-resistant rate of 3% was found among Candida species. Moreover, there was a statistically significant difference in MICs of fenticonazole and clotrimazole between the two most prevalent causative species, C. parapsilosis complex and C. albicans. Correct identification of the causative agents of onychomycosis and performing susceptibility testing could be helpful in choosing the most appropriate antifungal therapy.

2023-01-17·FEMS Microbiology Letters

Therapeutic effects of fenticonazole on bacterial vaginosis in mice

Article

作者: Peng, Peiran ; Dai, Hongbo ; Mei, Ru ; Zhu, Jun ; Yao, Chao ; Yu, Jinfen

AbstractBacterial vaginitis (BV) is a syndrome of increased vaginal discharge, fishy smelling leucorrhea, and itching and burning vulva caused by the microecological imbalance in the vagina induced by mixture of Gardnerella vaginalis (GV) and some anaerobic bacteria. Fenticonazole, an imidazole derivative and antimicrobial compound, has been demonstrated to exert effective therapeutic effects in mixed vaginitis. Accordingly, our study was designed to explore the potential role of fenticonazole in GV-infected BV mouse models. Female C57/BL6 mice were injected intraperitoneally with β-estradiol 3 days before and on the day of GV infection to maintain a pseudoestrus state. On the day of infection, mice were intravaginally inoculated with 20 µl of a suspension of GV (6 × 106 CFU/ml). Fenticonazole was administered as 2% vaginal cream (0.2 mg each mouse) by intravaginal application once a day for 3 days beginning the day of infection. At day 3 postinfection, the mice were sacrificed and vaginal washes were harvested. GV proliferation and Lactobacillus content were calculated in the vaginal lavage. Neutrophil counts in the vaginal lavage were observed through Pap staining. Myeloperoxidase (MPO) activity and proinflammatory cytokine (TNF-α, IL-1β, IL-6, iNOS, COX2, and NF-κB) levels in vaginal tissues were measured by ELISA and western blotting. Vaginal tissues were stained by hematoxylin and eosin (H&E) to examine the exfoliation of vaginal epithelial cells. GV infection increased GV proliferation and neutrophil counts but reduced Lactobacillus content in the vaginal lavage, as well as enhanced MPO activity, proinflammatory cytokine levels, and the exfoliation of vaginal epithelial cells in vaginal tissues of BV mouse models. However, administration of fenticonazole significantly ameliorated the above phenomena. Fenticonazole greatly improves the symptoms of GV-induced BV in mouse models.

2022-12-31·Drug Delivery2区 · 医学

Fenticonazole nitrate loaded trans-novasomes for effective management of tinea corporis: design characterization, in silico study, and exploratory clinical appraisal

2区 · 医学

ArticleOA

作者: Mosallam, Shaimaa ; Albash, Rofida ; Hassab, Mahmoud A. El ; El-Haggar, Radwan ; Eldehna, Wagdy M. ; Al-Rashood, Sara T. ; Ragaie, Maha H.

The current investigation aimed for loading fenticonazole nitrate (FTN), an antifungal agent with low aqueous solubility, into trans-novasomes (TNs) for management of tinea corporis topically. TNs contain Brij^® as an edge activator besides the components of novasomes (cholesterol, Span 60, and oleic acid) owing to augment the topical delivery of FTN. TNs were fabricated applying ethanol injection method based on D-optimal experiment. TNs were evaluated with regard to entrapment efficiency percent (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP). Further explorations were conducted on the optimum formulation (F7). F7 showed spherical appearance with EE%, PS, PDI, and ZP of 100.00 ± 1.10%, 358.60 ± 10.76 nm, 0.51 ± 0.004, and -30.00 ± 0.80 mV, respectively. The in silico study revealed the ability of the FTN-cholesterol complex to maintain favorable interactions throughout the molecular dynamics simulation (MDS) study. Moreover, Trichophyton mentagrophytes growth was inhibited effectively by F7 than by FTN suspension applying 2,3-bis(2-methyloxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay. Furthermore, a clinical appraisal on patients with tinea corporis fungal lesions confirmed the superiority of F7 compared to Miconaz^® cream in the magnitude of clinical cure of tinea corporis. Thereby, TNs could be considered as promising vesicles for enhancing the antifungal potential of FTN for the topical management of tinea corporis.

100 项与硝酸芬替康唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02583	硝酸芬替康唑	D01AC12 G01AF12	DB13434

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
真菌病	-	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
外阴阴道念珠菌病	临床3期	中国	山东特瑞林医药科技发展有限公司	2016-08-09
足癣	临床2期	中国	开封制药（集团）有限公司	2019-04-12
皮肤真菌病	临床1期	中国	南京海纳医药科技股份有限公司	2015-08-17